CD4 and neoplasm: Recent studies demonstrate that a subset of CD4+ T cells, referred to as CD4+CD25hi FoxP3+ naturally occurring Tregs, may accumulate in the tumor environment and suppress tumor-specific T-cell responses, thereby hindering tumor rejection25–27.